Sutton Wealth Advisors’s 10x Genomics TXG Stock Holding History

Sutton Wealth Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30	Closed	-$854	–	1712
2022 Q3	$854	Buy	+30	New	+$1.14K	﹤0.01%	1336
2022 Q1	–	Sell	-7	Closed	-$1.04K	–	1721
2021 Q4	$1.04K	Buy	+7	New	+$1.07K	﹤0.01%	1320

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sutton Wealth Advisors's TXG Position: Q4 2022 in Review

Sutton Wealth Advisors sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 30 shares — an estimated $854 sold.

Sutton Wealth Advisors first reported a position in TXG in Q4 2021 and held it in 2 quarters. The position peaked at $1.04K in Q4 2021. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

Sutton Wealth Advisors reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 30 10x Genomics shares in Q4 2022, an estimated $854.
Sutton Wealth Advisors first reported a position in 10x Genomics in Q4 2021 and held it in 2 quarters.
Sutton Wealth Advisors's 10x Genomics position peaked at $1.04K in Q4 2021.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on Sutton Wealth Advisors's 13F filing for Q4 2022, filed 7 Nov 2023.